Inclusion conjunctivitis

Summary

Inclusion conjunctivitis (MONDO:0005808) is a disease and 1 clinical trial. A subtype of chlamydia trachomatis infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	inclusion conjunctivitis
Mondo ID	MONDO:0005808
EFO	EFO:0007324
MeSH	D003235
DOID	DOID:13800
ICD-10-CM	A74.0
NCIT	C116817
SNOMED CT	231861005
UMLS	C0009770
MedGen	1095
Is cancer (heuristic)	no

Also known as: Chlamydial conjunctivitis · neonatal Chlamydia conjunctivitis

Disease family

This is a subtype of chlamydia trachomatis infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › commensal bacterial infectious disease › chlamydia trachomatis infectious disease › inclusion conjunctivitis

Related subtypes (3): trachoma, lymphogranuloma venereum, pneumonia caused by chlamydia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Azithromycin	Phase 3 (in late-stage trials)
Tetracycline	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01178762	Not specified	COMPLETED	The Effect of Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CHEMBL4299381	0	1